Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) Shares Outstanding (Weighted Average): 2010-2025

Historic Shares Outstanding (Weighted Average) for Anika Therapeutics (ANIK) over the last 16 years, with Sep 2025 value amounting to $14.4 million.

  • Anika Therapeutics' Shares Outstanding (Weighted Average) fell 2.56% to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year decrease of 2.56%. This contributed to the annual value of $14.6 million for FY2024, which is 0.03% up from last year.
  • Per Anika Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $14.4 million for Q3 2025, which was up 0.53% from $14.3 million recorded in Q2 2025.
  • Anika Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $14.8 million during Q1 2024, with a 5-year trough of $14.2 million in Q1 2025.
  • For the 3-year period, Anika Therapeutics' Shares Outstanding (Weighted Average) averaged around $14.6 million, with its median value being $14.6 million (2023).
  • As far as peak fluctuations go, Anika Therapeutics' Shares Outstanding (Weighted Average) grew by 1.56% in 2021, and later declined by 4.54% in 2025.
  • Anika Therapeutics' Shares Outstanding (Weighted Average) (Quarterly) stood at $14.4 million in 2021, then increased by 1.20% to $14.6 million in 2022, then increased by 0.21% to $14.6 million in 2023, then climbed by 0.03% to $14.6 million in 2024, then dropped by 2.56% to $14.4 million in 2025.
  • Its last three reported values are $14.4 million in Q3 2025, $14.3 million for Q2 2025, and $14.2 million during Q1 2025.